Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
amyloid beta
Biotech
BMS pays Leqembi originator $100M for Alzheimer's prospects
Bristol Myers has turned to the source of Leqembi to push into Alzheimer’s, paying BioArctic $100 million upfront for two preclinical antibodies.
Nick Paul Taylor
Dec 19, 2024 5:23am
Patient death prompts Roche to adjust Alzheimer's trial
Oct 30, 2024 11:40am
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer's drug
Oct 28, 2024 10:00am
Anti-nausea drug reduces Alzheimer's-advancing cells in mice
Sep 17, 2024 4:52pm
FDA revises guidance on predicting Alzheimer's drug benefits
Mar 12, 2024 7:40am
Alzheimer's transmission via procedure may boost prion theory
Jan 31, 2024 1:27pm
